More DaSkon Shield
U.S. District Court Judge Robert Merhige denied the company's request on July 23 to consolidate punitive damage claims related to the Dalkon Shield into a nationwide class action suit. Company acknowledged that a Chapter 11 proceeding is one of firm's "obvious options for an orderly global solution of the Dalkon Shield litigation".
You may also be interested in...
COVID-19 has disrupted the operational schedules of health care and technology providers alike to unparalleled levels in 2020. But scratch the surface, and outcomes-oriented, value-based health care targets remains a priority – albeit competing a little harder for attention at present.
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
Kim Trautman, who authored the US FDA’s Quality System Regulation in the 1990s, tells Medtech Insight that the agency probably won’t release a draft of its updated, harmonized QSR until next year thanks in part to a recent move by HHS secretary Alex Azar to personally sign off on every rule.